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INTRODUCTION
The PIERS project was run as a prospective multicentre international study in seven centres in Canada, 
the United Kingdom, New Zealand, and Australia. 
Standardized assessment, by means of  pre-printed orders 
for maternal and fetal surveillance, was used to document 
information about potential predictors of  a composite 
adverse maternal outcome developed by content experts 
through Delphi consensus.1 Standardization of  assessment 
has been shown to improve outcomes for a variety of  
conditions such as pulmonary embolism.2
The fullPIERS clinical prediction model was developed and 
validated for women with preeclampsia who were admitted 
to tertiary care hospitals.3 The inclusion and exclusion 
criteria are detailed elsewhere.3 The fullPIERS model 
identified the following predictors of  adverse maternal 
outcome within 48 hours of  admission: gestational age, 
chest pain or dyspnea, oxygen saturation, platelet count, 
serum creatinine, and serum aspartate transaminase 
concentration (for this model, the area under the curve of  
the receiver operating characteristic was 0.88, 95% CI 0.84 
to 0.92).4 There were, however, many other potential 
predictors considered, and many of  these clinical and 
laboratory measures are of  particular interest to clinicians. 
Univariable analyses related to these measures have also 
been discussed in a number of  separate publications.5,6
What may also be of  interest to clinicians, beyond the 
content of  PIERS, is the use in PIERS of  standardization 
of  clinical practice, and in particular, the experience of  
running the project as a continuous quality improvement 
project in some centres, while informed consent was 
required in others. In this commentary, we describe our 
experience and outline the implications of  these two 
approaches for patient recruitment, cost, and resource use.
CONTINUOUS QUALITY  
IMPROVEMENT AS RESEARCH
The divide between CQI and research has not always been 
clear. Historically, CQI was not considered research as it 
was a process of  reaction to bad outcomes.7 However, 
with improved study design and statistical methods, it is no 
longer considered a separate entity from research.
CQI provides infrastructure for conducting clinical and 
outcomes research and promotes evaluation in clinical 
practice.8 CQI projects use existing data (from medical 
records, databases, or registries) to learn from what is being 
done in clinical practice. The strength of  this approach lies 
in the ability to include all patients with a given condition, 
or at least a representative sample of  them. In contrast, 
requiring informed consent from individual patients 
introduces sampling bias into the type of  individual 
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enrolled, particularly when consent rates are low. This 
compromises the scientific validity of  the data and may 
bias participation towards those with less severe disease. 
Inter-hospital variability in consent rates may further 
magnify the bias and make its impact on outcomes more 
difficult to understand.
THE PIERS EXPERIENCE
Initially, PIERS was run in three centres (n = 943 women) 
as a CQI project and in four centres (n = 316 women) 
as a study requiring informed consent from women for 
secondary analysis of  existing data from their medical 
records. The choice of  methodology was dictated by 
the local research ethics board. Although the 2010 
Tri-Council Policy Statement does not require researchers 
to seek consent from individuals for the secondary use 
of  non-identifiable information9 (as in PIERS), research 
ethics boards in some PIERS centres in Canada required 
informed consent for study approval.
Consent Rates
In PIERS, centres that were required to obtain informed 
consent for data collection had consent rates of  29%, 
83%, 91%, and 92%. Coordinators gave many reasons 
for patients refusing to give informed consent and many 
of  those reasons were not surprising, such as lack of  
patient interest or inadequate English or French skills to 
understand the study explanation; however, an important 
reason for refusal of  consent was severe (as opposed to 
non-severe) preeclampsia, which is associated with the 
highest rates of  adverse outcomes. A critical number 
of  adverse outcomes are required to build an outcome 
prediction model, particularly when a large number of  
candidate predictors are considered.
As PIERS could not collect information on women who 
did not consent to PIERS data collection in non-CQI sites, 
we cannot comment on differences in outcomes related to 
informed consent. However, in the initial PIERS site, more 
adverse outcomes (5.1%) were seen when the study moved 
from obtaining informed consent to use standardized 
pre-printed orders for maternal and fetal assessment in 
preeclampsia than in the epoch when PIERS was run as 
a CQI project (0.7%) and all women admitted to hospital 
with preeclampsia underwent standardized assessment 
according to pre-printed orders (95% CI 0.04 to 0.49.10 
The transition to CQI also resulted in the pre-printed orders 
being used consistently for 92% of  women admitted with 
preeclampsia, compared with the previous epoch in which 
these orders were used for only 42% of  women who had 
given their informed consent for participation in PIERS.
Resources and Costs
Staffing also played a critical role in recruitment in non-
CQI PIERS centres. In one such centre, 66 women met 
PIERS eligibility criteria but were not recruited because of  
lack of  staff  to obtain consent from patients, particularly 
overnight and on weekends.
The PIERS research costs were higher in non-CQI 
sites. In both CQI and non-CQI sites, approximately 
seven hours were required for PIERS case identification, 
data retrieval from case files, data entry into the PIERS 
database, and resolution of  data queries from the central 
PIERS site. However, sites that were required to obtain 
informed consent for PIERS data collection required an 
additional 1.25 hours of  coordinator time, particularly as 
the consent process often took two visits. This additional 
time translates into higher costs, although a formal cost 
analysis was not performed.
PIERS in Relation to the Medical Literature
We were unable to identify pregnancy studies examining 
the impact on consent rates or outcomes of  informed 
consent for secondary data analysis. However, 
observations in studies outside pregnancy were consistent 
with the observations that we made during the conduct 
of  PIERS. A systematic review of  17 non-pregnancy 
studies identified highly variable published consent rates 
of  37% to 93% for data abstraction from existing medical 
records.11 These often low and variable rates of  consent 
were also seen in the Canadian Acute Stroke Registry when 
it was forced to transition from anonymous record review 
to informed consent; the consent rate was 51% even 
after a year’s experience in recruitment methods, and the 
inter-site variation in consent was 17%.12,13 This registry 
also identified the need for multiple visits to introduce the 
study, explain the procedures, and give ample opportunity 
to ask questions and make a decision about participation.12 
The bias in patients recruited was also illustrated by the 
significantly lower in-hospital mortality rate (6.9%) among 
patients who consented to registry participation, as 
opposed to those who did not (21.7%).12
A BROADER CONCEPT OF CONSENT
A recent commentary by Hansson argues for a broader 
understanding of  autonomy and informed consent.14 
It argues that having a restricted view of  autonomy 
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undermines the possibility of  patients participating in 
the development of  medical science. The author states 
that even if  there is limited risk of  harm (such as in a 
database/registry study), research ethics boards focus on 
the individual’s interest in having a say. However, this is 
at the expense of  a drop-out rate that may result in the 
inability to draw scientifically meaningful conclusions from 
the study. Instead, Hansson proposes an expanded view of  
autonomy in which there is no consent, but the individual 
has a right to know what type of  information is in the 
registry and has access to indirect means of  exercising 
insight and influencing decision-making,
CONCLUSION
There are lessons to be learned from PIERS in terms of  
both content and methods. The standardized assessment 
of  hospitalized women with preeclampsia in PIERS yielded 
great insights by standardizing what we do in routine 
clinical practice and auditing the results. However, in 
PIERS we saw research and financial challenges associated 
with requirements for informed consent for secondary 
analysis of  existing data that were similar to those seen in 
studies outside pregnancy. We urge research ethics boards 
and institutional review boards to consider carefully the 
impact of  requiring such an approach on research quality 
and costs, particularly as the Tri-Council policy does not 
require such an approach to protect an individual’s privacy.
ACKNOWLEDGEMENTS
We would like to thank the PIERS site co-ordinators 
(Lynn Bissonnette, Sherbrooke, QC; Laura Payant and 
Svetlana Shachkina, Ottawa, ON; Heather Ramshaw, 
Kingston, ON; Jane Hayes, Leeds, UK; Barbra Pullar, 
Christchurch, New Zealand; and Claire Parker, Subiaco, 
Australia).
REFERENCES
1. Linstone HA, Turoff  M. The Delphi Method: techniques and applications. 
Reading, MA: Adison-Wesley; 1975. ISBN 9780201042948. Available at: 
http://is.njit.edu/pubs/delphibook. Accessed January 11, 2012.
2. Wells PS, Ginsberg JS, Anderson DR, Kearon C, Gent M, Turpie AG,  
et al. Use of  a clinical model for safe management of  patients with 
suspected pulmonary embolism. Ann Intern Med 1998;129: 997–1005.
3. von Dadelszen P, Payne B, Li J, Ansermino JM, Broughton Pipkin F, 
Douglas MJ, et al.; for the PIERS Study Group. Prediction of  adverse 
maternal outcomes in pre-eclampsia: development and validation of  the 
fullPIERS model. Lancet 2011;377(9761):219–27. Comment in Lancet 
2011;377(9761):185–6.
4. PIERS Calculator. Available at: http://piers.cfri.ca/PIERSCalculatorH.aspx. 
Accessed August 23, 2011.
5. Payne B, Magee LA, Cote Anne-Marie, Hutcheon JA, Li Ji, Kyle PM,  
et al. PIERS proteinuria: relationship with adverse maternal and perinatal 
outcome. J Obstet Gynaecol Can 2011;33:588–97.
6. Millman AL, Payne B, Qu Ziguang, Douglas J, Hutcheon JA, Lee T, et al. 
Oxygen saturation as a predictor of  adverse maternal outcomes in women 
with pre-eclampsia. J Obstet Gynaecol Can 2011; 33:705–14.
7. American College of  Surgeons. Continuous quality improvement. Available 
at: http://www.facs.org/cqi/index.html. Accessed October 17, 2011.
8. Bellin E, Dubler NN. The quality improvement-research divide and the 
need for external oversight. Am J Public Health 2001;91:1512–7.
9. Canadian Institutes of  Health Research, Natural Sciences and Engineering 
Research Council of  Canada, Social Sciences and Humanities Research 
Council of  Canada. Tri-Council policy statement: ethical conduct for 
involving humans, 2010. Available at: http://www.pre.ethics.gc.ca/pdf/ 
eng/tcps2/TCPS_2_FINAL_Web.pdf. Accessed July 28, 2011.
10. Menzies J, Magee LA, Li J, Macnab YC, Yin R, Stuart H, et al. Instituting 
surveillance guidelines and adverse outcomes in preeclampsia. Obstet 
Gynecol 2007;110:121–7.
11. Kho ME, Duffet M, Willison DJ, Cook DJ, Brouwers MC. Written 
informed consent and selection bias in observational studies using medical 
records: systematic review. BMJ 2009;338:b866.
12. Tu JV, Willison DJ, Silver FL, Fang J, Richards JA, Laupacis A, et al. 
Impracticability of  informed consent in the Registry of  the Canadian Stroke 
Network. N Engl J Med 2004;350:1414–21.
13. Willison DJ, Kapral MK, Peladeau P, Richards JA, Fang J, Silver FL. 
Variation in recruitment across sites in a consent-based clinical data registry: 
1essons from the Canadian Stroke Network. BMC Med Ethics 2006;7:1–8.
14. Hansson M. Do we need a wider view of  autonomy in epidemiological 
research? BMJ 2010;340:1172–4.
